Search

Your search keyword '"Pulmonary fibrosi"' showing total 2 results
Start Over Descriptor "Pulmonary fibrosi" Publisher bmj publishing group
2 results on '"Pulmonary fibrosi"'

1. Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study

Author

Corrado Campochiaro, Giacomo De Luca, Maria-Grazia Lazzaroni, Giuseppe Armentaro, Amelia Spinella, Barbara Vigone, Barbara Ruaro, Anna Stanziola, Devis Benfaremo, Enrico De Lorenzis, Beatrice Moccaldi, Silvia Laura Bosello, Giovanna Cuomo, Lorenzo Beretta, Elisabetta Zanatta, Dilia Giuggioli, Nicoletta Del Papa, Paolo Airo, Marco Confalonieri, Gianluca Moroncini, Lorenzo Dagna, Marco Matucci-Cerinic, Campochiaro, C, De Luca, G, Lazzaroni, Mg, Armentaro, G, Spinella, A, Vigone, B, Ruaro, B, Stanziola, A, Benfaremo, D, De Lorenzis, E, Moccaldi, B, Bosello, Sl, Cuomo, G, Beretta, L, Zanatta, E, Giuggioli, D, Del Papa, N, Airo, P, Confalonieri, M, Moroncini, G, Dagna, L, Matucci-Cerinic, M., Campochiaro, C., De Luca, G., Lazzaroni, M. -G., Armentaro, G., Spinella, A., Vigone, B., Ruaro, B., Stanziola, A., Benfaremo, D., De Lorenzis, E., Moccaldi, B., Bosello, S. L., Cuomo, G., Beretta, L., Zanatta, E., Giuggioli, D., Del Papa, N., Airo, P., Confalonieri, M., Moroncini, G., and Dagna, L.

Subjects
pulmonary fibrosi, Settore MED/16 - REUMATOLOGIA, Rheumatology, pulmonary fibrosis, biological therapy, Immunology, scleroderma, systemic, therapeutics, Immunology and Allergy, scleroderma, systemic
Abstract

IntroductionNintedanib (NTD) has been shown to be effective in systemic sclerosis (SSc)-interstitial lung disease (ILD). Here we describe the efficacy and safety of NTD in a real-life setting.MethodsPatients with SSc-ILD treated with NTD were retrospectively evaluated at 12 months prior to NTD introduction; at baseline and at 12 months after NTD introduction. The following parameters were recorded: SSc clinical features, NTD tolerability, pulmonary function tests and modified Rodnan skin score (mRSS).Results90 patients with SSc-ILD (65% female, mean age 57.6±13.4 years, mean disease duration 8.8±7.6 years) were identified. The majority were positive for anti-topoisomerase I (75%) and 77 (85%) patients were on immunosuppressants. A significant decline in %predicted forced vital capacity (%pFVC) in the 12 months prior to NTD introduction was observed in 60%. At 12 months after NTD introduction, follow-up data were available for 40 (44%) patients and they showed a stabilisation in %pFVC (64±14 to 62±19, p=0.416). The percentage of patients with significant lung progression at 12 months was significantly lower compared with the previous 12 months (60% vs 17.5%, p=0.007). No significant mRSS change was observed. Gastrointestinal (GI) side effects were recorded in 35 (39%) patients. After a mean time of 3.6±3.1 months, NTD was maintained after dose adjustment in 23 (25%) patients. In nine (10%) patients, NTD was stopped after a median time of 4.5 (1–6) months. During the follow-up, four patients died.ConclusionsIn a real-life clinical scenario, NTD, in combination with immunosuppressants, may stabilise lung function. GI side effects are frequent and NTD dose adjustment may be necessary to retain the drug in patients with SSc-ILD.

Published
2023

2. Mapping and predicting mortality from systemic sclerosis

Author

Kamal Solanki, Roger Hesselstrand, Ulrich A Walker, Jiri Stork, Carlo Chizzolini, Stefan Heitmann, Vanessa Smith, Maurizio Cutolo, Simona Rednic, Carolina de Souza Müller, Jörg H W Distler, Luc Mouthon, Nicolas Hunzelmann, Edoardo Rosato, Mohammed Tikly, Franco Cozzi, Nemanja Damjanov, Paola Caramaschi, Florenzo Iannone, Sule Yavuz, Alexandra Balbir-Gurman, Marco Matucci-Cerinic, Duska Martinovic, Carlos Alberto Von Mühlen, Beatriz Joven, Carina Mihai, Oliver Distler, Paolo Airò, Emmanuel Chatelus, Paloma García de la Peña Lefebvre, Gabriela Riemekasten, Grégoire Rey, Marouane Boubaya, Jörg Henes, Alessandra Vacca, Ulf Müller-Ladner, Thierry Zenone, Armando Gabrielli, Srdan Novak, Ellen De Langhe, Juan José Alegre-Sancho, Walter Alberto Sifuentes-Giraldo, R. Becvar, Jacob M van Laar, Matthias Seidel, Carlomaurizio Montecucco, Daniela Opris, Esthela Loyo, Kilian Eyerich, Vera Ortiz Santamaria, Otylia Kowal-Bielecka, L. Ananieva, Muriel Elhai, Valeria Riccieri, Vanesa Cosentino, Christophe Meune, Panayiotis G. Vlachoyiannopoulos, Jérôme Avouac, Maria De Santis, Branimir Anić, Eric Hachulla, Susanne Ullman, Francesca Ingegnoli, Gabriella Szücs, Bojana Stamenkovic, Yannick Allanore, Serena Vettori, Maria João Salvador, László Czirják, Lisa K. Stamp, Elhai, Muriel, Meune, Christophe, Boubaya, Marouane, Avouac, Jã©rã´me, Hachulla, Eric, Balbir gurman, Alexandra, Riemekasten, Gabriela, Airã², Paolo, Joven, Beatriz, Vettori, Serena, Cozzi, Franco, Ullman, Susanne, Czirjã¡k, Lã¡szlã³, Tikly, Mohammed, Mã¼ller ladner, Ulf, Caramaschi, Paola, Distler, Oliver, Iannone, Florenzo, Ananieva, Lidia P, Hesselstrand, Roger, Becvar, Radim, Gabrielli, Armando, Damjanov, Nemanja, Salvador, Maria J, Riccieri, Valeria, Mihai, Carina, Szã¼cs, Gabriella, Walker, Ulrich A, Hunzelmann, Nicola, Martinovic, Duska, Smith, Vanessa, Mã¼ller, Carolina De Souza, Montecucco, Carlo Maurizio, Opris, Daniela, Ingegnoli, Francesca, Vlachoyiannopoulos, Panayiotis G, Stamenkovic, Bojana, Rosato, Edoardo, Heitmann, Stefan, Distler, Jã¶rg H. W, Zenone, Thierry, Seidel, Matthia, Vacca, Alessandra, Langhe, Ellen De, Novak, Srdan, Cutolo, Maurizio, Mouthon, Luc, Henes, Jã¶rg, Chizzolini, Carlo, Mã¼hlen, Carlos Alberto Von, Solanki, Kamal, Rednic, Simona, Stamp, Lisa, Anic, Branimir, Santamaria, Vera Ortiz, Santis, Maria De, Yavuz, Sule, Sifuentes giraldo, Walter Alberto, Chatelus, Emmanuel, Stork, Jiri, Laar, Jacob Van, Loyo, Esthela, De La Peã±a Lefebvre, Paloma Garcia, Eyerich, Kilian, Cosentino, Vanesa, Alegre sancho, Juan Jose, Kowal bielecka, Otylia, Rey, Grã©goire, Matucci cerinic, Marco, and Allanore, Yannick

Subjects
pulmonary fibrosi, 0301 basic medicine, Male, Genetics and Molecular Biology (all), Time Factors, Databases, Factual, systemic sclerosis, Disease, Biochemistry, Scleroderma, 0302 clinical medicine, cardiovascular disease, Risk Factors, Cause of Death, Epidemiology, Immunology and Allergy, skin and connective tissue diseases, Cause of death, BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina, ddc:616, education.field_of_study, Framingham Risk Score, integumentary system, Orvostudományok, Middle Aged, Prognosis, 3. Good health, Quartile, Cohort, epidemiology, Female, France, systemic sclerosi, pulmonary fibrosis, Aged, Death Certificates, Humans, Proportional Hazards Models, Scleroderma, Systemic, Rheumatology, Immunology, Biochemistry, Genetics and Molecular Biology (all), Human, medicine.medical_specialty, Time Factor, Prognosi, Population, Klinikai orvostudományok, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, Databases, Internal medicine, cardiovascular disease, epidemiology, pulmonary fibrosis, systemic sclerosis, medicine, education, BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine, Factual, 030203 arthritis & rheumatology, Proportional hazards model, business.industry, Risk Factor, Systemic, Surgery, 030104 developmental biology, Death Certificate, Proportional Hazards Model, business
Abstract

ObjectivesTo determine the causes of death and risk factors in systemic sclerosis (SSc).MethodsBetween 2000 and 2011, we examined the death certificates of all French patients with SSc to determine causes of death. Then we examined causes of death and developed a score associated with all-cause mortality from the international European Scleroderma Trials and Research (EUSTAR) database. Candidate prognostic factors were tested by Cox proportional hazards regression model by single variable analysis, followed by a multiple variable model stratified by centres. The bootstrapping technique was used for internal validation.ResultsWe identified 2719 French certificates of deaths related to SSc, mainly from cardiac (31%) and respiratory (18%) causes, and an increase in SSc-specific mortality over time. Over a median follow-up of 2.3 years, 1072 (9.6%) of 11 193 patients from the EUSTAR sample died, from cardiac disease in 27% and respiratory causes in 17%. By multiple variable analysis, a risk score was developed, which accurately predicted the 3-year mortality, with an area under the curve of 0.82. The 3-year survival of patients in the upper quartile was 53%, in contrast with 98% in the first quartile.ConclusionCombining two complementary and detailed databases enabled the collection of an unprecedented 3700 deaths, revealing the major contribution of the cardiopulmonary system to SSc mortality. We also developed a robust score to risk-stratify these patients and estimate their 3-year survival. With the emergence of new therapies, these important observations should help caregivers plan and refine the monitoring and management to prolong these patients’ survival.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results